Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Care management intervention strategies

13 evidence topics · 17 sources

Three-phase psychological support model used in COMP360 trials
Payer coverage criteria and reauthorization proposed for psilocybin

“All payer participants agreed that coverage criteria would align with the FDA-approved product label including, for instance, the quantity and frequency of treatment, and would comply with the REMS requirements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Several added they would look to previous experience with esketamine for guidance and that coverage criteria for psilocybin may be similar.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Whereas some participants would accept provider attestation for continuation of therapy, others would require documentation of improvement and sustained treatment response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One PBM participant suggested that reviewing claims for other TRD treatments subsequent to psilocybin administration could further support determination of treatment response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants discussed reimbursement considerations with coverage of psilocybin including developing a bundled payment model combining all related services (eg, medication, administration, psychotherapy) into a single billable episode of care” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote